5608 Results

People

  1. Motzer
    Motzer
  2. Scher
    Scher
  3. Solit
    Solit
  4. Morris
    Morris
  5. Bajorin
    Bajorin
  6. Rosenberg
    Rosenberg
  7. Berger
    Berger
  8. Iyer
    Iyer
  9. Reuter
    Reuter
  10. Feldman
    Feldman

Groups

  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)
  7. Surgery (1000)
  8. Epidemiology and Biostatistics (864)
  9. Survivorship Research (773)
  10. Urology (769)
  1. "Genitourinary Oncology Service"
Formats
  1. Journal Article (2745)
  2. Meeting Abstract (2507)
  3. Review (113)
  4. Book Section (82)
  5. Editorial (52)
  6. Correspondence (33)
  7. Conference Paper (29)
  8. Guidelines (24)
  9. Research Letter (15)
  10. Book Whole (4)
  11. Miscellaneous (4)
Groups
  1. Genitourinary Oncology Service (5608)
  2. Solid Tumor Oncology Division (5608)
  3. Department of Medicine (5598)
  4. GSK Faculty (1640)
  5. Human Oncology and Pathogenesis Program (1139)
  6. Department of Pathology and Laboratory Medicine (1034)

More Groups

People
  1. Robert Motzer (1243)
  2. Howard Scher (1130)
  3. David Solit (779)
  4. Dean Bajorin (657)
  5. Michael Morris (577)
  6. Jonathan Rosenberg (510)

More People

Years
  1. 2025 (118)
  2. 2024 (293)
  3. 2023 (283)
  4. 2022 (314)
  5. 2021 (341)
  6. 2020 (352)

More Years

Publications
  1. Journal of Clinical Oncology (1697)
  2. Annals of Oncology (303)
  3. Clinical Cancer Research (282)
  4. Cancer Research (245)
  5. Cancer (125)
  6. European Urology (118)

More Publications

Publishers
  1. American Society of Clinical Oncology (1757)
  2. American Association for Cancer Research (688)
  3. Oxford University Press (408)
  4. Elsevier Science, Inc. (389)
  5. Elsevier Inc. (384)
  6. Nature Publishing Group (294)

More Publishers

Results (5608)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Transitional cell carcinoma (TCC): Status of investigations with ifosfamide, paclitaxel, and cisplatin (ITP)
    Meeting Abstract

    Bajorin, D. F.; Dodd, P. M.; McCaffrey, J. A.; Hilton, S.; Mazumdar, M.; Donat, S.; Herr, H.; Icasiano, E.; Higgins, G.
    Seminars in Oncology (1999)

    Fulltext@MSK | Save
  • Paclitaxel/cisplatin/ifosfamide in advanced bladder cancer
    Meeting Abstract

    Bajorin, D. F.
    Seminars in Oncology (1999)

    Fulltext@MSK | Save
  • Detection of circulating tumor cells in prostatic carcinoma (PC) using immunobead reverse transcriptase polymerase chain reaction (RT PCR) for prostatic specific membrane antigen (PSMA) mRNA
    Meeting Abstract

    Ghossein, R.; Osman, I.; Bhattacharya, S.; Ferrara, J.; Fazzari, M.; Scher, H.
    Laboratory Investigation (1999)

    Fulltext@MSK | Save
  • Fractionated radioimmunotherapy with I-131-labeled chimeric antibody G250 (cG250) in patients with metastatic renal cell carcinoma
    Meeting Abstract

    Divgi, C. R.; O'Donoghue, J. A.; McGagh, D. A.; Motzer, R. J.; Anwar, K.; Sheikh, A.; Gonzalez, R. S.; Welt, S.; Old, L. J.; Larson, S. M.
    Journal of Nuclear Medicine (1999)

    Fulltext@MSK | Save
  • Increased sensitivity in the detection of circulating prostatic tumor cells in peripheral blood after immunobead enrichment and RT-PCR for prostate specific membrane antigen (PSMA) mRNA
    Meeting Abstract

    Bhattacharya, S.; Osman, I.; Ferrara, J.; Scher, H. I.; Ghossein, R. A.
    Journal of Histochemistry and Cytochemistry (1999)

    Fulltext@MSK | Save
  • Fractionated radioimmunotherapy with I-131 chimeric antibody G250 (cG250) in metastatic renal cancer
    Meeting Abstract

    Divgi, C. R.; O'Donoghue, J. A.; McGagh, D.; Anwar, K.; Motzer, R.; Welt, S.; Larson, S. M.; Old, L. J.
    European Journal of Nuclear Medicine (1999)

    Fulltext@MSK | Save
  • [F-18]2-fluoro-2-doxyglucose (FDG) and C-11-methionine (C-11 MET) positron emission tomography (PET) versus conventional imaging modalities (CIM) in patients with newly progressing metastatic prostate cancer
    Meeting Abstract

    Nunez, R.; Macapinlac, H.; Yeung, H. W. D.; Akhurst, T.; Finn, R. D.; Osman, I.; Petrisko, R.; Scher, H. I.; Larson, S. M.
    European Journal of Nuclear Medicine (1999)

    Fulltext@MSK | Save
  • The use of the prostate xenograft CWR22 and its androgen independent sublines in the preclinical development of herceptin
    Meeting Abstract

    Higgins, B.; Fox, W. D.; Maiese, K.; Fazzari, M.; Scher, H. I.; Agus, D. B.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa™), an inhibitor of EGF receptor tyrosine kinase
    Meeting Abstract

    Sirotnak, F. M.; Miller, V. A.; Scher, H. I.; Kris, M. G.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo
    Meeting Abstract

    Sirotnak, F. M.; Bornmann, W. G. B.; Miller, V. A.; Scher, H. I.; Kris, M. G.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save